U.S. Aerospace & Defense Stock News

Progyny (PGNY) has just posted its FY 2025 numbers, with fourth quarter revenue of US$318.4 million and basic EPS of US$0.15, alongside trailing twelve month revenue of about US$1.3 billion and basic EPS of US$0.68. Over the past few quarters, revenue has ranged from US$313.3 million to US$332.9 million with basic EPS moving between US$0.15 and US$0.20, while trailing net income excluding extra items sits at US$58.5 million across the last year. For investors, the headline story focuses on...

If you are looking at AtriCure and wondering whether the current share price reflects its true worth, you are not alone. Many investors are asking the same question right now. The stock recently closed at US$31.25, with returns of a 4.1% decline over 7 days, a 17.3% decline over 30 days and a 20.4% decline year to date, adding to a 19.3% decline over 1 year, a 21.7% decline over 3 years and a 51.0% decline over 5 years. These moves have put more attention on how AtriCure is being valued,...

Covista (CVSA) stock is back in focus after the company used its Investor Day to relaunch under a new name, outline its Purpose at Scale plan, and reaffirm multi year revenue guidance through 2029. See our latest analysis for Covista. Despite the Investor Day updates and long term guidance, Covista’s recent 30 day share price return of a 15.39% decline has taken some heat out of the stock, even as its 3 year total shareholder return of 149.06% and 5 year total shareholder return of 152.78%...

WaFd stock at a glance WaFd (WAFD) shares have been under pressure recently, with a 1 day return of about a 4.4% decline and negative moves over the past week and month as investors reassess regional bank exposure. See our latest analysis for WaFd. That recent 4.4% 1 day share price decline and softer 7 day and 30 day share price returns sit against a more resilient picture, with WaFd posting a 1 year total shareholder return of 9.1% and positive results over 3 and 5 years. This suggests...

Ramaco Resources reported fourth-quarter 2025 sales of US$128.01 million and a net loss of US$14.71 million, alongside a full-year 2025 net loss of US$51.45 million on sales of US$536.62 million, while also being served with a putative securities class action tied to disclosures about its Brook Mine rare earth project. At the same time, the company outlined progress at Brook Mine and highlighted stronger liquidity following recent financings, underlining how its rare earth ambitions and...

Agilysys (NasdaqGS:AGYS) has been selected by luxury resort Rudding Park to deliver a unified hospitality management platform. The multi year agreement will see Agilysys technology replace fragmented systems across the resort's guest and back office operations. The deal expands Agilysys's presence in high end hospitality, using Rudding Park as a live reference site for its end to end software suite. For investors watching Agilysys, the Rudding Park win lands at a time when the shares trade...

Manchester United (NYSE:MANU) has dismissed manager Ruben Amorim after a brief and costly tenure. Michael Carrick has been appointed interim manager, with early shifts in team performance under his leadership. The club reports a profitability turnaround driven by cost cutting, following recent financial challenges. Manchester United, listed on the NYSE under ticker MANU, is both a football club and a global sports and entertainment brand. The club operates across matchday, media, and...

Chemed (CHE) is back in focus after its fourth quarter and full year 2025 results came in below analyst expectations, with softer margins, cautious 2026 guidance, and operational pressure at both VITAS and Roto Rooter. See our latest analysis for Chemed. That earnings miss and softer 2026 guidance appear to be weighing on sentiment, with a 7 day share price return of 13.72% and a year long total shareholder return of 31.39% pointing to fading momentum despite the buyback activity. If Chemed's...

Recent performance and context for APi Group APi Group (APG) has been drawing attention after a period of mixed short term moves and stronger longer term returns, prompting investors to reassess how its safety and specialty services business is currently priced. See our latest analysis for APi Group. With the share price at US$44.46 after a 6.1% 1 month share price return and a 14.1% year to date share price return, the much stronger 69.8% 1 year total shareholder return suggests momentum has...

S&P Global (NYSE:SPGI) is hosting the 44th annual CERAWeek conference to address key transformations in global energy markets. The event brings together policymakers, industry leaders, and experts to discuss technology, geopolitics, and energy transition themes. The conference highlights S&P Global's role in energy information, analytics, and thought leadership across the sector. S&P Global, best known for its credit ratings and index businesses, also has a large information and analytics...

Recent performance snapshot for Fortive (FTV) With no single headline event driving Fortive (FTV) today, the stock’s recent performance and fundamentals offer the clearest starting point as you think about where it may fit in a portfolio. Over the past month, Fortive’s share price return is 12.1%, compared with a 10.7% gain over the past 3 months and a small negative total return of 0.9% over the past year. Year to date, the stock shows a 6.9% total return, while its 3 year and 5 year total...

In late February 2026, Novavax reported Q4 2025 revenue of US$147.14 million and net income of US$17.53 million, marking a move from loss-making to profitable operations for both the quarter and full year. This earnings swing was heavily supported by partnership-driven milestone payments and improved cost efficiency, underscoring how its collaboration-led model is now a central driver of profitability. Next, we’ll examine how this partnership-fueled return to profitability reshapes...

In the past week, an investigation on behalf of long-term Marex Group plc (NASDAQ: MRX) investors was announced, alleging multi-year accounting schemes involving off-balance-sheet entities, fictitious transactions, and misleading disclosures that may have rendered the company’s financial statements inconsistent and unreliable. The complaint’s focus on potential breaches of fiduciary duties and the integrity of Marex’s reported profits raises direct questions about the quality and...

Navan (NasdaqGS:NAVN) is facing securities fraud class action lawsuits tied to its recent IPO, focused on alleged gaps in disclosures around marketing spend and business trajectory. At the same time, the company has rolled out a major AI powered upgrade to its Meetings & Events platform, aimed at corporate travel and events management. Navan has also signed new enterprise partnerships, adding high profile clients while legal proceedings related to the IPO get under way. Navan operates in...

In recent weeks, Cooper Companies has attracted attention as insiders, including senior executives, bought shares while analysts reiterated positive views ahead of the March 5 earnings release. At the same time, The London Company’s new position and expectations that earnings and revenue for the January 2026 quarter will exceed last year’s levels have reinforced market focus on Cooper’s contact lens and women’s health businesses. Next, we’ll examine how this insider buying and analyst...

Procter & Gamble (NYSE:PG) is returning as a top-level sponsor of USA Gymnastics for the 2028 Los Angeles Olympics. This marks the first time a partner has re-signed with USA Gymnastics since its recent scandals. The agreement is expected to increase P&G’s brand presence and consumer engagement around the home Olympics. For a consumer products group like Procter & Gamble, which owns a broad portfolio of everyday household and personal care brands, high profile sports partnerships are one...

Escalade (ESCA) has wrapped up FY 2025 with fourth quarter revenue of US$62.6 million and basic EPS of US$0.27, alongside trailing twelve month revenue of US$240.2 million and EPS of US$1.00, supported by a trailing net profit margin of 5.7%. Over recent periods the company has seen quarterly revenue move from US$63.9 million and EPS of US$0.20 in Q4 2024 to US$67.8 million and EPS of about US$0.40 in Q3 2025 before landing at Q4 2025 levels. Trailing EPS has ranged between roughly US$0.92...

If you are wondering whether Tidewater's share price still offers value or if most of the opportunity is already reflected, this article is going to focus squarely on what the numbers are saying about valuation. Tidewater's stock last closed at US$79.42, with returns of 8.2% over 7 days, 30.3% over 30 days, 52.1% year to date and 74.1% over 1 year. This naturally raises questions about how much of the story is already priced in. Recent attention around Tidewater has centred on its role in...

Exzeo Group FY 2025 Earnings Snapshot Exzeo Group (XZO) has wrapped up FY 2025 with fourth quarter revenue of US$55.4 million and basic EPS of US$0.25, capping a year in which trailing twelve month revenue reached US$221.3 million and EPS came in at US$0.99 alongside very large year over year net earnings growth. Over recent periods, revenue has moved from US$44.7 million in Q4 FY 2024 to US$55.4 million in Q4 FY 2025, while quarterly basic EPS has shifted from US$0.14 to roughly US$0.25,...

If you are wondering whether Cboe Global Markets is still reasonably priced after a strong run, this article walks through what the current share price might be implying about the company’s value. With the stock at US$299.72 and recent returns of 3.8% over 7 days, 13.3% over 30 days, 20.8% year to date, 43.8% over 1 year, 145.9% over 3 years and 206.7% over 5 years, many investors are asking what is already priced in. Recent coverage has focused on Cboe Global Markets’ position as a major...

Oportun Financial (OPRT) has wrapped up FY 2025 with fourth quarter revenue of US$189.8 million and basic EPS of US$0.07, alongside net income of US$3.4 million. Its trailing twelve month numbers sit at US$725.2 million in revenue and EPS of US$0.53 on net income of US$25.2 million. Over recent periods the company has seen quarterly revenue move between US$174.8 million and US$194.2 million, with basic EPS ranging from a loss of US$0.75 to a profit of US$0.21. This gives investors a clearer...

If you are wondering whether Haemonetics shares are quietly offering value at around US$63.32, you are not alone. Many investors are asking the same question right now. The stock is up 3.5% over the past week, although that sits against a 4.1% decline over 30 days, a 20.8% decline year to date, and a 3.3% decline over the past year, which may have reshaped how investors think about its risk and return profile. These returns also sit alongside a 18.8% decline over three years and a 47.3%...

Euronet Worldwide (EEFT) just reported its fourth quarter 2025 results, with sales and net income figures that support its recent completion of a large buyback totaling more than 15 million shares since 2022. See our latest analysis for Euronet Worldwide. Even with the recent buyback and solid fourth quarter, the share price has eased, with a 7 day share price return of 4.1% decline and a 1 year total shareholder return of 32.1% decline. This suggests sentiment is still cautious despite the...

In February 2026, U.S. Physical Therapy reported fourth-quarter and full-year 2025 results showing higher revenue but lower quarterly net income, announced a 10-year alliance that will place ten subsidiary clinics into a local hospital system’s network, raised its quarterly dividend to US$0.46, and disclosed an upcoming CFO transition. Taken together, the new hospital partnership, dividend increase, and earnings mix highlight how U.S. Physical Therapy is balancing growth initiatives with...